PMID- 25696794
OWN - NLM
STAT- MEDLINE
DCOM- 20150427
LR  - 20220310
IS  - 1943-7722 (Electronic)
IS  - 0002-9173 (Linking)
VI  - 143
IP  - 3
DP  - 2015 Mar
TI  - Diagnostic and prognostic value of BCL2 rearrangement in 53 patients with 
      follicular lymphoma presenting as primary skin lesions.
PG  - 362-73
LID - 10.1309/AJCP4SUBR4NPSPTN [doi]
AB  - OBJECTIVES: To study the diagnostic value of BCL2 rearrangement in follicle 
      center lymphoma (FCL) presenting as primary skin lesions, evaluate its prevalence 
      and the prognostic value in primary cutaneous FCL (PCFCL), and assess prognostic 
      factors in PCFCL. METHODS: Fifty-three patients with a cutaneous presentation of 
      FCL without a history of nodal lymphoma were selected retrospectively. Clinical 
      and histologic data were collected together with staging and follow-up data. A 
      fluorescence in situ hybridization (FISH) test for BCL2 split probes was 
      performed on skin biopsy specimens. RESULTS: Initial staging procedures 
      identified 47 PCFCLs and six cases of secondary skin involvement of FCL (SSIFCL). 
      FISH detected seven cases carrying a BCL2 rearrangement: four (8.5%) of 47 PCFCLs 
      and three (50%) of six SSIFCLs. These seven cases coexpressed BCL2 and CD10. In 
      PCFCL, cutaneous relapse rate was 42.6%. A small/medium centrocytic cell 
      population was associated with a higher probability of skin relapse in univariate 
      (P = .008) and multivariate (P = .028) analysis, and BCL2 rearrangement detection 
      was associated with secondary extracutaneous spreading (P = .05). CONCLUSIONS: We 
      observed that BCL2 rearrangement in PCFCL is rare, associated with initial 
      positivity of staging (diagnostic value) or with secondary extracutaneous 
      spreading (prognostic value). In selected cases with BCL2-CD10 coexpression, FISH 
      testing could detect patients with poor outcome and require closer monitoring.
CI  - Copyright(c) by the American Society for Clinical Pathology.
FAU - Pham-Ledard, Anne
AU  - Pham-Ledard A
AD  - From the Dermatology Department, CHU de Bordeaux, Bordeaux, France; EA2406 
      Histology and Molecular Pathology of Tumours, University of Bordeaux, Bordeaux, 
      France; anne.pham-ledard@chu-bordeaux.fr.
FAU - Cowppli-Bony, Anne
AU  - Cowppli-Bony A
AD  - Clinical Epidemiology Unit, CHU de Bordeaux, Bordeaux, France; and.
FAU - Doussau, Adelaide
AU  - Doussau A
AD  - Clinical Epidemiology Unit, CHU de Bordeaux, Bordeaux, France; and.
FAU - Prochazkova-Carlotti, Martina
AU  - Prochazkova-Carlotti M
AD  - EA2406 Histology and Molecular Pathology of Tumours, University of Bordeaux, 
      Bordeaux, France;
FAU - Laharanne, Elodie
AU  - Laharanne E
AD  - EA2406 Histology and Molecular Pathology of Tumours, University of Bordeaux, 
      Bordeaux, France; Pathology Department, CHU de Bordeaux, Bordeaux, France.
FAU - Jouary, Thomas
AU  - Jouary T
AD  - From the Dermatology Department, CHU de Bordeaux, Bordeaux, France;
FAU - Belaud-Rotureau, Marc-Antoine
AU  - Belaud-Rotureau MA
AD  - EA2406 Histology and Molecular Pathology of Tumours, University of Bordeaux, 
      Bordeaux, France;
FAU - Vergier, Beatrice
AU  - Vergier B
AD  - EA2406 Histology and Molecular Pathology of Tumours, University of Bordeaux, 
      Bordeaux, France; Pathology Department, CHU de Bordeaux, Bordeaux, France.
FAU - Merlio, Jean-Philippe
AU  - Merlio JP
AD  - EA2406 Histology and Molecular Pathology of Tumours, University of Bordeaux, 
      Bordeaux, France; Pathology Department, CHU de Bordeaux, Bordeaux, France.
FAU - Beylot-Barry, Marie
AU  - Beylot-Barry M
AD  - From the Dermatology Department, CHU de Bordeaux, Bordeaux, France; EA2406 
      Histology and Molecular Pathology of Tumours, University of Bordeaux, Bordeaux, 
      France;
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (BCL2 protein, human)
RN  - 0 (Biomarkers)
RN  - 0 (DNA, Neoplasm)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers
MH  - DNA, Neoplasm/genetics
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - *Gene Rearrangement
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphoma, Follicular/*genetics/pathology
MH  - Male
MH  - Middle Aged
MH  - *Neoplasm Recurrence, Local
MH  - Polymerase Chain Reaction
MH  - Prognosis
MH  - Proto-Oncogene Proteins c-bcl-2/*genetics
MH  - Recurrence
MH  - Retrospective Studies
MH  - Skin/pathology
MH  - Skin Neoplasms/*genetics/pathology
OTO - NOTNLM
OT  - BCL2 rearrangement
OT  - FISH
OT  - Follicular lymphoma
OT  - Primary cutaneous follicle center lymphoma
OT  - Translocation t(14;18)
EDAT- 2015/02/20 06:00
MHDA- 2015/04/29 06:00
CRDT- 2015/02/20 06:00
PHST- 2015/02/20 06:00 [entrez]
PHST- 2015/02/20 06:00 [pubmed]
PHST- 2015/04/29 06:00 [medline]
AID - 143/3/362 [pii]
AID - 10.1309/AJCP4SUBR4NPSPTN [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2015 Mar;143(3):362-73. doi: 10.1309/AJCP4SUBR4NPSPTN.